Carbon Ion Radiotherapy for Hepatocellular Carcinoma (HCC)

In Japan, HCC accounts for 95% of all primary liver cancers. Since 85% of the HCC incidence develops from cirrhosis of the liver, the underlying cause of advanced liver insufficiency, it is essential that HCC therapy should have a high degree of radicality to cure the target tumor and a low level of invasiveness to spare the liver tissue so as ensure its resistance to the subsequent treatment interventions. While the various therapies currently available all have their particular limitations, it is certainly no exaggeration to note that there has been no procedure so far that has both a high radicality and low invasiveness while also being effective against large cancers.NIRS-CNAO Joint Symposium on Carbon Ion Radiotherap